REGENXBIO Inc. (RGNX) is scheduled to report additional interim data from its phase II AAVIATE trial, including full six-month results from Cohorts 5 and 6, at the Hawaiian Eye and Retina meeting today, i.e. January 16, 2024.
AAVIATE is a phase II trial of the company's lead gene therapy program ABBV-RGX-314 using suprachoroidal delivery for the treatment of wet AMD.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.